Please enable JS

Investors & Media

2016 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
Dec-16-2016CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology. The parties to the agreement include the co-owners of the intell... 
Printer Friendly Version
Nov-22-2016CRISPR Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at the Lotte New York Palace Hotel, New York. Event: 28th Annual P... 
Printer Friendly Version
Nov-21-2016CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two presentations during the 58th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA on December 3rd-6th, 2016.  The two presentations will highlight recent work in re-creating the natural condition of hereditary persistence of feta... 
Printer Friendly Version
Nov-08-2016CRISPR Therapeutics to Present at the Stifel 2016 Healthcare Conference
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at the Lotte New York Palace Hotel, New York. Event: Stifel 2016 Healthcare Conference ... 
Printer Friendly Version
Nov-01-2016Casebia Therapeutics Press Release: Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer
Joint venture between CRISPR Therapeutics and Bayer grounds leadership team presence in Cambridge, MA with strategic Chief Executive Officer hire CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, today announced that James W. Burns, Ph.D. has been appointed President and Chief Executive Officer. Dr. Burns brings to Casebia Therapeutics nearly 30 years of R&D experience in the biopharmaceutical industry and a proven track ... 
Printer Friendly Version
Oct-18-2016CRISPR Therapeutics Announces Pricing of Initial Public Offering
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to 600,000 additional common shares at t... 
Printer Friendly Version
Jun-24-2016CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing
Funding to Support the Development of its CRISPR/Cas9 Gene-Editing Platform and Programs BASEL, Switzerland and Cambridge, Massachusetts – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional investment brings the total Series B financing round to nearly $140 million. The previous Series B investment was ... 
Printer Friendly Version
Jun-08-2016CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
CRISPR Therapeutics Gains Exclusive Worldwide License to Proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) Technology with Initial Research Focused on Duchenne Muscular DystrophyBASEL, Switzerland and ILLKIRCH GRAFFENSTADEN, France– June 8, 2016 – CRISPR Therapeutics and Anagenesis Biotechnologies today announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis' proprietary Paraxial Mesoderm Multipotent Cells (... 
Printer Friendly Version
Mar-17-2016CRISPR Therapeutics Adds Pablo J. Cagnoni, M.D., to Board of Directors and Names Tony Coles, M.D., Chairman of the Board to Enhance Drug Development and Commercialization Expertise
BASEL, Switzerland and CAMBRIDGE, Massachusetts – March 17, 2016 – CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Pablo J. Cagnoni, M.D., to its board of directors. The Company also named current board member, Tony Coles, M.D., as new Chairman of the Board. Dr. Coles succeeds Bradley Bolzon, M.D., Managing Director of Versant Ventures and Founding Chairman since 2013... 
Printer Friendly Version
Mar-10-2016CRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer
BASEL, Switzerland and CAMBRIDGE, Massachusetts – March 10, 2016 – CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Marc Becker as Chief Financial Officer to further support the Company's efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform. Mr. Becker is a seasoned executive who brings more than 20 years of e... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet